Loading
A phase 3 trial of SH-1028 tablets in non-small-cell lung cancer, run by Nanjing Sanhome Pharmaceutical, Co., Ltd., now recruiting.
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations is a phase 3 interventional study registered as NCT06080776 by Nanjing Sanhome Pharmaceutical, Co., Ltd., with 242 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-02-01. Interventions recorded: SH-1028 tablets and Placebo SH-1028 tablets.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.